Consolidated Portfolio Review Corp Amgen Inc Transaction History

Consolidated Portfolio Review Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 29, 2024	SELL	$255.7 - $288.46 $53,952 - $60,865	-211 Reduced 18.61%	923 $266 Million
Q3 2023 Nov 13, 2023	BUY	$218.65 - $271.46 $18,803 - $23,345	86 Added 8.21%	1,134 $305 Million
Q2 2023 Aug 14, 2023	SELL	$214.27 - $253.37 $10,927 - $12,921	-51 Reduced 4.64%	1,048 $233 Million
Q1 2023 May 11, 2023	BUY	$225.79 - $275.2 $248,143 - $302,444	1,099 New	1,099 $266 Million

3,123

409M

7.56M

7.2M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Consolidated Portfolio Review Corp, based on Form 13F filings with the SEC.

Stay updated on Consolidated Portfolio Review Corp with notifications on news.